Science and Technology Science and Technology
Mon, January 20, 2025
[ 08:02 PM ] - WOFL
10 new museums opening in 2025
[ 07:22 PM ] - TechCrunch
UK to unveil 'Humphrey' assistant for civil servants with other AI plans to cut bureaucracy
[ 06:22 PM ] - MSN
Ahead of Quad meet, EAM meets Australia, Japanese counterparts in Washington
[ 05:22 PM ] - MSN
Scientists discover tiny galaxy that pressed 'pause' for 2.5 billion years
[ 04:42 PM ] - MSN
AstraZeneca secures first BTK approval in first-line mantle cell lymphoma
[ 04:42 PM ] - SlashGear
10 Awesome Pieces Of Japanese Tech You Didn't Know Existed
[ 01:22 PM ] - NextBigFuture
SpaceX Starship Roadmap Lower Launch Costs by 100 Times
[ 12:42 PM ] - MSN
Smartwatches reveal insights into psychiatric illnesses and genetic links
[ 12:02 PM ] - MSN
Scientists Seek 'Dark Oxygen' in Ocean Depths To Unlock Life's Secrets
[ 11:42 AM ] - MSN
Tiny vortexes help detect dangerous viruses
[ 11:42 AM ] - MSN
World's smallest biomedical robot advances interventional diagnosis and treatment
[ 09:42 AM ] - MSN
US TikTok revives, and Trump's tech takeover? ...Tech and Science Daily podcast
[ 09:22 AM ] - MSN
Construction Materials as a Solution for Carbon Dioxide Storage
[ 09:02 AM ] - MSN
Youth unemployment crisis worsens as AI redefines global labour markets
[ 08:42 AM ] - MSN
Tamil Nadu: Scientific Community, Activists Conde .. as Director V Kamakoti's Cow Urine Remarks; VIDEO
[ 07:22 AM ] - MSN
Chennai hosting training programme for science teachers
[ 06:42 AM ] - SHINE
Shanghai launches engine fund for fast-tracking science to market
[ 06:22 AM ] - MSN
In Search of Solutions: How Vishwasrao Salunkhe W .. y Through the Healthcare Sector to Make an Impact
[ 06:22 AM ] - MSN
Chief of top Indian university sparks backlash for promoting 'medicinal value' of cow urine
[ 06:02 AM ] - MSN
Jaishankar meets foreign ministers of QUAD nations
[ 06:02 AM ] - WRVO
Syracuse STEAM High School now accepting applications
[ 04:42 AM ] - cybernews
US Treasury sanctions Chinese cybersecurity firm and hacker behind US network breaches
[ 04:42 AM ] - MSN
5 biggest space conspiracy theories in human history
[ 04:22 AM ] - SpaceNews
China performs high altitude reusable rocket test with uncertain outcome
[ 03:42 AM ] - Reuters
European shares steady as Trump's inauguration takes centre stage
[ 03:22 AM ] - MSN
DOST Releases Multi Language Disaster Preparednes .. Guide to Enhance Earthquake and Tsunami Readiness
[ 02:42 AM ] - Tuko
Jack Black's mom, Judith Love Cohen, who was an aerospace engineer
[ 02:22 AM ] - Forbes
"Masters Of Collaboration" - Inside Gothenburg's Sustainable Ecosystem
[ 12:22 AM ] - news10nbc
What to stream: Julia Louis-Dreyfus, Morris Chestnut, 'The Wild Robot' and 'The Night Agent'
Sun, January 19, 2025
[ 11:22 PM ] - MSN
IITian Baba expelled from Juna Akhara for abusing; engineer-turned sanyasi refutes

AstraZeneca secures first BTK approval in first-line mantle cell lymphoma


Published on 2025-01-20 16:42:28 - MSN
  Print publication without navigation

  • The approval of Calquence marks the first and only BTK inhibitor approved for the first-line treatment of MCL in the US.

AstraZeneca has received its first approval for a BTK inhibitor, Calquence (acalabrutinib), in combination with bendamustine and rituximab for the first-line treatment of mantle cell lymphoma (MCL), a rare and aggressive form of non-Hodgkin lymphoma. This approval by the European Commission marks a significant advancement as it offers a new treatment option for MCL patients who are not eligible for stem cell transplant. The approval was supported by data from the ECHO trial, which demonstrated that the combination therapy significantly improved progression-free survival compared to standard treatments. This development not only expands AstraZeneca's oncology portfolio but also provides a less toxic alternative to traditional chemotherapy, potentially improving patient outcomes and quality of life.

Read the Full MSN Article at:
[ https://www.msn.com/en-us/science/biochemistry/astrazeneca-secures-first-btk-approval-in-first-line-mantle-cell-lymphoma/ar-AA1xxTxt ]
Contributing Sources